Psoriasis: Comorbidities and associations

Giornale Italiano di Dermatologia e Venereologia

Volumn 146, Issue 1, 2011, Pages 9-15

  Farley, E ^a   Menter, A ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autoimmune diseases; Psoriasis; Skin diseases

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 17; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ALCOHOL CONSUMPTION; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); CROHN DISEASE; DEPRESSION; DISEASE ASSOCIATION; ENTERITIS; HEPATITIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; METABOLIC SYNDROME X; OBESITY; PSORIASIS; REVIEW; T CELL LYMPHOMA;

EID: 79955754842     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496-509.
2. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med 1979;301:555. (Pubitemid 9258270)
3. Ellis CN, Gorsulowsky DC, Hamilton TA, Billings JK, Brown MD, Headington JT et al. Cyclosporine improves psoriasis in a double- blind study. JAMA 1986,256:3110-6. (Pubitemid 17045825)
4. Gisondi P, Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non disease-specific risk factors. Semin Thromb Hemost 2009;35:313-24.
5. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7. (Pubitemid 29418506)
6. Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. Seminars in Cutaneous Medicine and Surgery 2010;29:10-5.
7. Kim N, Thrash B, Menter A. Comorbidities in psoriasis. Semin Cutan Med Surg 2010;29:10-5.
8. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X et al. The risk of mortality in patients with psoriasis: results form a population-based study. Arch Dermatol 2007;143:1493-9.
9. Menter A, Griffiths CEM, Tebbey PW, Horn EW, Sterry W. Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. J Eur Acad Dermatol Venereo 2010 [E-pub ahead of print].
10. Kourosh AS, Miner A, Menter A. Psoriasis as the marker of underlying systemic disease. Skin Therapy Letter 2008;13:1-5.
11. Prey S, Paul C, Bronsard V, Puzenat E, Gourraud PA, Aractingi S et al. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol 2010;24:23-30.
12. Salvarani C, Lo Scocco G, Macchioni P, Cremonesi T, Rossi F, Mantovani W et al. Prevalence of psoriatic arthritis in Italian psoriatic patients. J Rheumatol 1995;22:1499-503.
13. Scarpa R, Oriente P, Pucino A, Torella M, Vignone L, Riccio A et al. Psoriatic arthritis in psoriatic patients. Br J Rheumatol 1984;23:246-50.
14. Alenius GM, Stenberg B, Stenlund H, Lundblad M, Dahlqvist SR. Inflammatory joint manifestations are prevalent in psoriasis: preva lence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire. J Rheumatol 2002;29:2577-82. (Pubitemid 35416965)
15. Gottlieb AB, Kircik L, Eisen D, Jackson JM, Boh EE, Strober BE et al. Use of etanercept for psoriatic arthritis in the dermatology clinic: The experience diagnosing, understanding care, and treatment with etanercept (EDUCATE) study. J Dermatol Treat 2006;17:343-52. (Pubitemid 46895587)
16. Gladmann DD. Mortality in psoriatic arthritis. Clin Exp Rheumatol 2008;26:62-5.
17. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patiens with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167-72. (Pubitemid 44749774)
18. Friedewald VE Jr, Cather JC, Gordon KB, Kavanaugh A, Ridker PM, Roberts WC. The Editor's Roundtable: psoriasis, inflammation, and coronary artery disease. Am J Cardiol 2008;101:1119-26.
19. Friedewald VE, Cather JC, Gelfand JM, Gordon KB, Gibbons GH, Grundy SM et al. AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol 2008;102:1631-43.
20. Fink AM, Cauza E, Hassfeld W, Dunky A, Bayer PM, Jurecka W et al. Vascular endothelial growth factor in patients with psoriatic arthritis. Clin Exp Rheumatol 2007;25:305-8. (Pubitemid 46851437)
21. Caligiuri G, Kaveri SV, Nicoletti A. IL-20 and atherosclerosis: another brick in the wall. Arterioscler Thromb Vasc Biol 2006;26:1929-30.
22. Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA. High prevalence of subclinical atheroscle rosis in psoriatic arthritis patients without clinically evident car diovascular disease or classic atherosclerosis risk factors. Arthirtis Rheum 2007;57:1074-80. (Pubitemid 47237336)
23. Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, Amigo-Diaz E, Testa A, Garcia-Porrua C et al. Endothelial dysfunction in psoriatic arthirits patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007;57:287-293.
24. Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol 2003;48:805-21.
25. Nair RP, Henseler T, Jenisch S, Stuart P, Bichakjian CK, Lenk W et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet 1997;6:1349-56.
26. Broadley SA, Deans J, Sawcer SJ, Clayton D, Compston DA. Au toimmune disease in first degree relatives of patients with multiple sclerosis: A UK survey. Brain 2000;123:1102-11. (Pubitemid 30312103)
27. Liu Y, Helms C, Liao W, Zaba LC, Duan S, Gardner J et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. Genet 2008;4:e1000041.
28. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseas es. J Am Acad Dermatol 1999;41:401-7. (Pubitemid 29418506)
29. Schmitt J, Ford DE. Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample. J Eur Acad Dermatol Venereol 2010;24:885-92.
30. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life. Arch Dermatol 2001;137:280-4.
31. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998;139:84650.
32. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomized phase III trial. Lancet 2006;367:29-33.
33. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP et al. Impact of obesity and smoking on psoriasis presen tation and management. Arch Dermatol 2005;141:1527-34. (Pubitemid 41815842)
34. Setty AR, Curhan G, Choi HK. Smoking and the risk of psoriasis in women: Nurses' health study II. Am J Med 2007;120:953-9. (Pubitemid 350011082)
35. Poikolainen K, Reunala T, Karvonen J. Smoking, alcohol and life events related to psoriasis among women. Br J Dermatol 1994;130:473-7. (Pubitemid 24204666)
36. Duffy DL, Spelman LS, Martin NG. Psoriasis in Australian twins. J Am Acad Dermatol 1993;29:428-34. (Pubitemid 23260131)
37. Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: Results from a population based study in the United Kingdom. Arch Dermatol 2003;139:1425-9. (Pubitemid 37433132)
38. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Der matol 2006;126:2194-201. (Pubitemid 44413165)
39. Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev 2006;15:2069-77. (Pubitemid 44877028)
40. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity Among US Adults, 1999-2008. JAMA 2010;303:235-41.
41. Berghofer A, Pischon T, Reinhold T. Obesity prevalence from a European perspective: a systematic review. BMC Public Health. 2008,8:200.
42. Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007;157:649-55. (Pubitemid 47389868)
43. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with pso riasis. J Am Acad Dermatol 2006;55:829-35. (Pubitemid 44556851)
44. Henseler T, Christophers E. Disease concomitance in psoriasis. J AM Acad Dermaol 1995;32:982-6.
45. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Internal Med 2007;167:1670-5. (Pubitemid 47280349)
46. Murray MI, Bergstresser PR, Adams-Huet B, Cohen JB. Relationship of psoriasis severity to obesity using same-gender siblings as controls for obesity. Clin Exp Dermaol 2009;34:140-4.
47. Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Eng J Med 2008;358:241-51.
48. Hamminga EA, van der Lely AJ, Neumann HA, Thio HB. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypothese 2006;67:768-73. (Pubitemid 44062144)
49. Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M et al. CD8+ effector T cells contribute to macrohpage recruitment and adipose tissue inflammation in obesity. Nat Med 2009;15:914-20.
50. Feuerer M, Herrero L, Cipolletta D et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parapmeters. Nat Med 2009;15:930-9.
51. Goodman WA, Levine AD, Massari JV, Sugiyama H, McCormick TS, Cooper KD. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 2009;183:3170-6.
52. Naldi L, Addis A, Chimenti S, Giannetti A, Picardo M, Tomino C et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the psocare project. Dermatology 2008;217:365-73.
53. de Menezes Ettinger JE, Azaro E, de Souza CA, dos Santos Filho PV, Mello CA, Neves M Jr et al. Remission of psoriasis after open gastric bypass. Obes Surg 2006;16:94-7.
54. Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator blinded clinical trial. Am J Clin Nutr 2008;88:1242-7.
55. Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br J Dermatol 2008; 159:1331-1337.
56. Boehncke S, Thaci D, Beschmann H, Ludwig RJ, Ackermann H, Badenhoop K et al. Psoriasis patients show signs of insulin resist ance. Br J Dermaol 2007;157:1249-51. (Pubitemid 350115673)
57. Wolf N, Quaranta M, Prescott NJ, Allen M, Smith R, Burden AD et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet 2008;45:114-6. (Pubitemid 351252875)
58. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lan cet 2005;365:1415-28. (Pubitemid 40523737)
59. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiology 2010;28:1113-32.
60. Sommer DM, Jenish S, Suchan M, Christophers E. Increased Prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298:321-8.
61. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007;157:68-73. (Pubitemid 46934281)
62. Johnston A, Amadottir S, Gudjonsson JE, Aphale A, Sigmarsdottir AA, Gunnarsson SI et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 2008;159:342-50. (Pubitemid 352009847)
63. Cerman AA, Bozkurt S, Sav A, Tulunay A, Elbasi MO, Ergun T. Serum leptin levels, skin leptin and leptin receptor expressio in psoriasis. Br J Dermatol 2008;159:820-6.
64. Chen YJ, Wu CY, Shen JL, Chu SY, Chen CK, Chang YT et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008;144:1571-5.
65. Kaur S, Zilmer K, Kairane C, Kals M, Zilmer M. Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br J Dermatol 2008;159:1364-7.
66. Tarantino G, Saldalamacchia G, Conca P, Arena A. Non-alcoholic fatty lifver disease: further expression of the metabolic syndrome J Gastroenterol Hepatol 2007;22:293-303.
67. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21.
68. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaques disease. J Hepatology 2009;51:758-46.
69. Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol 2008;26:55-62.
70. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C et al. Infliximab induction and maintenance therapy for moderate-to- severe psoriasis: a phase III, multicentre double-blind trial. Lancet 2005;366:1367-74. (Pubitemid 41443403)
71. Chalmers RJ, Kirby B, Smith A, Burrows P, Little R, Horan M et al. Replacement of routine liver biopsy by procollagen III aminopep tide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 2005;152:444-50. (Pubitemid 40547117)
72. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guideliens of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermaol 2009;61:451-85.
73. Dreiher J, Weitzman D, Shapiro J, Davidovici B, Cohen AD. Psoriasis and chronic obstructive pulmonary disease: A case control study. Br J Dermatol 2008;159:956-60.
74. Xue-quin Y, You L. Study of sleep quality in patients with psoriasis. Institute of Aviation Medicine. J Invest Dermaol 2007;127:1809.
75. Reed WB, Becker SW, Rohde R, Heiskell CL. Psoriasis and arthritis clinicopathologic study. Arch Dermatol 1961;83:541-8.
76. Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermaol 2007;156:271-6. (Pubitemid 46095954)
77. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41. (Pubitemid 44547793)
78. Gelfand JM, Dommasch ED, Shin DB, Azfar RS, Kurd SK, Wang X et al. The risk of stroke in patients with psoriasis. J Investig Dermatol 2009;129:2411-8.
79. Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular disease and mortality. Arch Dermatol 2009;145:700-3.
80. Goulding JM, Price CL, Defty CL. Erectile dysfunction in patients with psoriasis: increased prevalence, an unmet need, and a chance to intervene. Br J Dermatol 2010 [E-pub ahead of printing].
81. Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 2009;145:379-82.